Palmoplantar dyshidrotic eczema related to secukinumab

Authors

  • Fiorella Bertani General Hospital of Acute Dr. Teodoro Álvarez, Autonomous City of Buenos Aires, Argentina
  • Laura Weintraub General Hospital of Acute Dr. Teodoro Álvarez, Autonomous City of Buenos Aires, Argentina
  • María Laura García Bazarra General Hospital of Acute Dr. Teodoro Álvarez, Autonomous City of Buenos Aires, Argentina.
  • Graciela Sánchez General Hospital of Acute Dr. Teodoro Álvarez, Autonomous City of Buenos Aires, Argentina.
  • Gladys Merola General Hospital of Acute Dr. Teodoro Álvarez, Autonomous City of Buenos Aires, Argentina.

DOI:

https://doi.org/10.47196/da.v26i4.2160

Keywords:

secukinumab, palmoplantar dyshidrotic eczema, palmoplantar dyshidrosis

Abstract

The use of biological agents for the treatment of psoriasis makes it possible to develop a long-term therapeutic strategy, but as a result of a possible imbalance in the immune response profiles it introduces new adverse effects. Cutaneous adverse reactions related to the use of secukinumab are rare, the most common being urticaria and infections. We present the case of a patient with psoriasis who manifested palmoplantar vesicular dermatitis after starting treatment with secukinumab.

Author Biographies

Fiorella Bertani, General Hospital of Acute Dr. Teodoro Álvarez, Autonomous City of Buenos Aires, Argentina

Medical Specialist in Dermatology. General Hospital of Acute Dr. Teodoro Álvarez.

Laura Weintraub, General Hospital of Acute Dr. Teodoro Álvarez, Autonomous City of Buenos Aires, Argentina

Plant Physician Specialist in Dermatology. General Hospital of Acute Dr. Teodoro Álvarez.

María Laura García Bazarra, General Hospital of Acute Dr. Teodoro Álvarez, Autonomous City of Buenos Aires, Argentina.

Plant Physician Specialist in Dermatology. General Hospital of Acute Dr. Teodoro Álvarez.

Graciela Sánchez, General Hospital of Acute Dr. Teodoro Álvarez, Autonomous City of Buenos Aires, Argentina.

Anatomopathologist. General Hospital of Acute Dr. Teodoro Álvarez.

Gladys Merola, General Hospital of Acute Dr. Teodoro Álvarez, Autonomous City of Buenos Aires, Argentina.

Head of the Dermatology Service. General Hospital of Acute Dr. Teodoro Álvarez.

References

I. Li J, Chen X, Liu Z, Yue Q, et ál. Expression of Th17 cytokines in skin lesions of patients with psoriasis. J Huazhong Univ Sci Technolog Med Sci 2007;27:330-332.

II. Lavieri A, Acevedo A, Baccarini E, Bourren P, et ál. Consenso nacional de psoriasis. Sociedad Argentina de Dermatología. 2020 [en línea]. Disponible en https://sad.org.ar/wp-content/uploads/2020/09/CONSENSO-NACIONAL-DE-PSORIASIS.-ACTUALIZACION-2020.-.pdf (Consulta: noviembre 2020)

III. Reich K, Warren RB, Coates LC, Di Comite G. Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. J Eur Acad Dermatol Venereol 2020;34:1161-1173.

IV. Bose R, Beecker J. Dyshidrotic eczema in two patients on secukinumab for plaque psoriasis: A case report. SAGE Open Med Case Rep 2020;8:1-4.

V. Pariser D, Frankel E, Schlessinger J, Poulin Y, et ál. Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies. Dermatol Ther (Heidelb) 2018;8:17‐32.

VI. Sladden MJ, Sladden CS, Gulliver WPF. Secukinumab-Induced Psoriasiform Eruption. JAMA Dermatol. 2017; 153:1194-1195.

VII. Ho PH, Tsai TF. Development of bullous pemphigoid during secukinumab treatment for psoriasis. J Dermatol. 2017;44:e220-e221.

VIII. Blackcloud P, Dupuy E, Kang Y, Smart C, et ál. Bullous acral eruption related to secukinumab. Dermatol. Online J 2019; 25:1-4.

IX. Naranjo CA, Busto U, Sellers EM, Sandor P, et ál. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245.

Downloads

Published

2020-12-20

Issue

Vol. 26 No. 4 (2020): October-December 2020

Section

Clinical Cases

License

El/los autor/es tranfieren todos los derechos de autor del manuscrito arriba mencionado a Dermatología Argentina en el caso de que el trabajo sea publicado. El/los autor/es declaran que el artículo es original, que no infringe ningún derecho de propiedad intelectual u otros derechos de terceros, que no se encuentra bajo consideración de otra revista y que no ha sido previamente publicado.

 

Le solicitamos haga click aquí para imprimir, firmar y enviar por correo postal la transferencia de los derechos de autor